Biography
<< Back
Susan E. Siegel 63
Independent Director
Elected
| Experience: | |
| 2017 - 2019 | Chief Innovation Officer, GE (conglomerate company) |
| 2012 - 2017 | CEO, GE Ventures and Licensing (conglomerate company) |
| Prior | General Partner, Mohr Davidow Ventures (multidisciplinary |
| investment firm; Ms. Siegel focused investments in | |
| personalized medicine, life sciences and digital health) | |
| Director and President, Affymetrix (genomics company) |
Other Board Positions
Illumina, Inc. (2019 - present)
Nevro Corporation (2020 - present)
The Engine (2016 - 2020), Chair (2020 - present)
KFF (formerly Kaiser Family Foundation) (2019 - present)
National Venture Capital Association (2012 - 2016)
Pacific Biosciences, Inc. (2006 - 2013)
Tech Interactive (2003 - 2007)
Affymetrix (2000 - 2006)
Notable Experience and Key Board Contributions
- Ms. Siegel brings extensive experience in identifying, funding, pioneering, and implementing industry-shifting innovations in the life sciences, biomedical research, and healthcare industries.
- Ms. Siegel led Affymetrix, one of the fastest growing genomics companies of its time. She led it from a pre-revenue startup to a multi-billion dollar publicly listed company that helped shape the emerging genomics industry, including addressing the bioethical issues of its day.
- Ms. Siegel has been recognized in Fortune’s “34 Leaders Who Are Changing Health Care,” as one of “The 100 Most Influential Women in Silicon Valley,” “Fierce Biotech’s Top 10 Women in Medical Devices,” and was awarded the “Lifetime Achievement Award” by Global Corporate Venture in 2020. She is an Aspen Institute Henry Crown Fellow and is a featured “Multiplier” in the bestselling book: “Multipliers: How the Best Leaders Make Everyone Smarter.”
Education
B.S. in Biology from the University of Puerto Rico
M.S. in Biochemistry and Molecular Biology from Boston University Medical School.